Polar Capital Healthcare Opportunities I GBP (IE00B3NLDF60)
67.01
+0.34
(+0.51%)
GBP |
Apr 16 2026
Returns Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Key Stats
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| -- | -- | -- | -- |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -- | -- |
Basic Info
| Investment Strategy | |
| None |
| General | |
| Security Type | None |
| Equity Style | None |
| Broad Asset Class | None |
| Broad Category | None |
| Global Peer Group | None |
| Peer Group | None |
| Global Macro | None |
| US Macro | None |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | None |
| Fund Owner Firm Name | None |
| Broad Asset Class Benchmark Index | |
| None | |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
--
--
Peer Group Low
--
Peer Group High
1 Year
% Rank:
--
--
Peer Group Low
--
Peer Group High
3 Months
% Rank:
--
--
Peer Group Low
--
Peer Group High
3 Years
% Rank:
--
--
Peer Group Low
--
Peer Group High
6 Months
% Rank:
--
--
Peer Group Low
--
Peer Group High
5 Years
% Rank:
--
--
Peer Group Low
--
Peer Group High
YTD
% Rank:
--
--
Peer Group Low
--
Peer Group High
10 Years
% Rank:
--
--
Peer Group Low
--
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of April 20, 2026.
Asset Allocation
| Type | % Net |
|---|---|
| Cash | -- |
| Stock | -- |
| Bond | -- |
| Convertible | -- |
| Preferred | -- |
| Other | -- |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Eli Lilly & Co. | 9.66% | 921.70 | -0.57% |
| Chugai Pharmaceutical Co., Ltd. | 6.00% | 56.62 | 3.90% |
|
ROCHE HOLDING AG
|
5.81% | -- | -- |
| argenx SE | 5.76% | 839.00 | -6.23% |
| Teva Pharmaceutical Industries Ltd. | 5.72% | 32.34 | -0.19% |
|
TORRENT PHARMACEUTICALS LTD ORD
|
4.79% | -- | -- |
| Fresenius SE & Co. KGaA | 4.66% | 54.35 | 0.00% |
| Enliven Therapeutics, Inc. | 3.63% | 47.46 | -1.35% |
|
UNIPHAR PLC ORD
|
3.55% | -- | -- |
| Novo Nordisk A/S | 3.52% | 39.15 | 1.91% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | -- |
| Actual Management Fee | -- |
| Administration Fee | -- |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | -- |
| General Availability | |
| Available for Insurance Product | -- |
| Available for RRSP | -- |
| Purchase Details | |
| Open to New Investors | -- |
| Minimum Initial Investment | -- |
| Minimum Subsequent Investment | -- |
Basic Info
| Investment Strategy | |
| None |
| General | |
| Security Type | None |
| Equity Style | None |
| Broad Asset Class | None |
| Broad Category | None |
| Global Peer Group | None |
| Peer Group | None |
| Global Macro | None |
| US Macro | None |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | None |
| Fund Owner Firm Name | None |
| Broad Asset Class Benchmark Index | |
| None | |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM | -- |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | -- |
| Stock | |
| Weighted Average PE Ratio | -- |
| Weighted Average Price to Sales Ratio | -- |
| Weighted Average Price to Book Ratio | -- |
| Weighted Median ROE | -- |
| Weighted Median ROA | -- |
| ROI (TTM) | -- |
| Return on Investment (TTM) | -- |
| Earning Yield | -- |
| LT Debt / Shareholders Equity | -- |
| Number of Equity Holdings | -- |
Growth Metrics
| EPS Growth (1Y) | -- |
| EPS Growth (3Y) | -- |
| EPS Growth (5Y) | -- |
| Sales Growth (1Y) | -- |
| Sales Growth (3Y) | -- |
| Sales Growth (5Y) | -- |
| Sales per Share Growth (1Y) | -- |
| Sales per Share Growth (3Y) | -- |
| Operating Cash Flow - Growth Rate (3Y) | -- |
Fund Details
| Key Dates | |
| Inception Date | -- |
| Last Annual Report Date | -- |
| Last Prospectus Date | -- |
| Share Classes | |
| IE00B28YJN35 | -- |
| IE00B28YJP58 | -- |
| IE00B28YJQ65 | -- |
| IE00B3K83P04 | -- |
| IE00B3K93X10 | -- |
| IE00B3NLSS43 | -- |
| IE00B3NLTK32 | -- |
| IE00B3NM2Q33 | -- |
| IE00BF12WY77 | -- |
| IE00BKSBD728 | -- |
| IE00BKSBD835 | -- |
| IE00BKSBD942 | -- |
| IE00BKSBDB61 | -- |
| Attributes | |
| Index Fund | -- |
| Inverse Fund | -- |
| Leveraged Fund | -- |
| Fund of Funds | -- |
| Currency Hedged Fund | -- |
| Socially Responsible Fund | -- |
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:IE00B3NLDF60", "name") |
| Broad Asset Class: =YCI("M:IE00B3NLDF60", "broad_asset_class") |
| Broad Category: =YCI("M:IE00B3NLDF60", "broad_category_group") |
| Prospectus Objective: =YCI("M:IE00B3NLDF60", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |